Published in Gene Therapy Weekly, October 4th, 2001
The therapeutic vaccine to be developed under the agreement will use Virax's platform technology, Co-X-Gene in FPV (fowlpox virus) vector. The prostate cancer program represents an additional application for the technology, which is currently being used in phase I/IIa clinical trial testing Co-X-Gene in FPV for the treatment of HIV.
A short list of leads has been selected for the prostate cancer development program and will undergo testing to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.